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background:  Treatment of in-stent restenosis (ISR) of the femoropopliteal (FP) vessels is challenging. The safety and acute procedural 
outcomes of the JetStream Navitus device in treating FP ISR have not been previously reported.
methods: The JetStreamISR is a pilot prospective registry that evaluated JetStream atherectomy (JA) in treating FP ISR. In-hospital 
serious adverse events (SAE) and acute procedural and device outcomes are presented. SAE was defined as any event leading to 
disability, death or prolonged hospital stay. Secondary endpoints included vascular death, amputation, vascular complications, distal 
embolization (DE) requiring further treatment and major bleeding. Acute procedural success was defined as ≤ 30% residual stenosis (via 
Quantitative Vascular Analysis (QVA)) and with no SAE. Acute device success was defined as ≤ 50% residual stenosis (via QVA) with no 
adjunctive balloon angioplasty (PTA) and with no SAE.
results:  30 patients (mean age 71.6 ± 12 years, 33% males) were included in this analysis. Mean ankle brachial index (ABI) 0.74 ± 0.29, 
diabetes 36.7%, current smoker 36.7%, lesion length 161 ±118 mm, lesion severity 80.1 ± 15.5%, vessel diameter 5.3 ± 0.6 mm. Device 
variables were: blades down (min) 3 ± 1.8, blades up (min) 2.5 ± 1.7, total run time (min) 5.6 ± 3.3. Adjunctive PTA was performed in all 
patients. Embolic filter protection (EFP) was used in 46.7% of patients. Bailout stenting was 6.9%. Acute procedural success occurred in 
100% of patients. Acute device success was 93.1%. DE requiring additional treatment occurred in 2 patients, one in a thrombotic-restenotic 
lesion and no filter used; the other was secondary to the JetStream caught on the filter wire. Among patients receiving a filter (n=14), 87.7% 
had no or micro embolization; 12.3% had visible macro debris. There were no procedure related death, vascular complication or major 
bleeding. No device-stent interaction was seen.
Conclusion: JA had favorable results in treating FP ISR with excellent acute procedural and device success, low stenting rate and overall 
low rate of DE. There were no SAE or device related stent complications.
